Population pharmacokinetics and pharmacodynamics of 500 mg oral dose levofloxacin in respiratory tract infection patients

Yusuke Tanigawara, Takako Shimizu, Kyoichi Totsuka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We analyzed levofloxacin(LVFX) population pharmacokinetics, and pharmacokinetics and pharmacodynamics(PK-PD) in Japanese subjects to evaluate a new 500 mg once-daily oral dosage regimen in Japan. Subjects were each orally administered once-daily LVFX 500 mg and plasma concentrations were measured; 1,362 concentrations of LVFX from 49 healthy or renally impaired subjects and 151 patients with respiratory tract infections were used for analysis. Population pharmacokinetic parameters were estimated using a non-linear mixed effects model(NONMEM), applying a 2-compartment model with first-order absorption as a pharmacokinetic model. Covariates were tested for potential influence on LVFX pharmacokinetics. Significant influence was found from creatinine clearance on oral clearance (CL t/F), body weight, and age on the apparent volume of distribution of the central compartment (V1/F), and food intake on absorption constant (k a). Based on the population pharmacokinetic models and the distribution of minimum inhibitory concentration(MIC) for clinical isolates of Streptococcus pneumoniae, LVFX PK-PD parameters in patients administered 500 mg once-daily, 100 mg three-times daily, 200 mg twice or three-times daily were calculated by Monte-Carlo simulation. It showed that 93.5% of patients with 500 mg LVFX once daily reached C max/MIC≥5, whereas 31.4% of those with 100 mg three times daily reached the target. The proportion of patients showing AUC 0-24h/ MIC≥30 exceeded 95% under both dosing regimens. These results indicate that 500 mg LVFX once daily is to be effective comparable to 100 mg three times daily, and is to be more appropriate dose for respiratory tract infection patients to prevent the emergence of LVFX resistance.

Original languageEnglish
Pages (from-to)47-54
Number of pages8
JournalJapanese Journal of Chemotherapy
Volume57
Issue numberSUPPL. 2
Publication statusPublished - 2009 Jul

Fingerprint

Levofloxacin
Respiratory Tract Infections
Pharmacokinetics
Population
Microbial Sensitivity Tests
Streptococcus pneumoniae
Area Under Curve
Creatinine
Japan
Eating
Body Weight

Keywords

  • Levofloxacin
  • PK-PD
  • Population pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Population pharmacokinetics and pharmacodynamics of 500 mg oral dose levofloxacin in respiratory tract infection patients. / Tanigawara, Yusuke; Shimizu, Takako; Totsuka, Kyoichi.

In: Japanese Journal of Chemotherapy, Vol. 57, No. SUPPL. 2, 07.2009, p. 47-54.

Research output: Contribution to journalArticle

@article{1d0db3a66bf64d8992c0d3c1a5e1a32d,
title = "Population pharmacokinetics and pharmacodynamics of 500 mg oral dose levofloxacin in respiratory tract infection patients",
abstract = "We analyzed levofloxacin(LVFX) population pharmacokinetics, and pharmacokinetics and pharmacodynamics(PK-PD) in Japanese subjects to evaluate a new 500 mg once-daily oral dosage regimen in Japan. Subjects were each orally administered once-daily LVFX 500 mg and plasma concentrations were measured; 1,362 concentrations of LVFX from 49 healthy or renally impaired subjects and 151 patients with respiratory tract infections were used for analysis. Population pharmacokinetic parameters were estimated using a non-linear mixed effects model(NONMEM), applying a 2-compartment model with first-order absorption as a pharmacokinetic model. Covariates were tested for potential influence on LVFX pharmacokinetics. Significant influence was found from creatinine clearance on oral clearance (CL t/F), body weight, and age on the apparent volume of distribution of the central compartment (V1/F), and food intake on absorption constant (k a). Based on the population pharmacokinetic models and the distribution of minimum inhibitory concentration(MIC) for clinical isolates of Streptococcus pneumoniae, LVFX PK-PD parameters in patients administered 500 mg once-daily, 100 mg three-times daily, 200 mg twice or three-times daily were calculated by Monte-Carlo simulation. It showed that 93.5{\%} of patients with 500 mg LVFX once daily reached C max/MIC≥5, whereas 31.4{\%} of those with 100 mg three times daily reached the target. The proportion of patients showing AUC 0-24h/ MIC≥30 exceeded 95{\%} under both dosing regimens. These results indicate that 500 mg LVFX once daily is to be effective comparable to 100 mg three times daily, and is to be more appropriate dose for respiratory tract infection patients to prevent the emergence of LVFX resistance.",
keywords = "Levofloxacin, PK-PD, Population pharmacokinetics",
author = "Yusuke Tanigawara and Takako Shimizu and Kyoichi Totsuka",
year = "2009",
month = "7",
language = "English",
volume = "57",
pages = "47--54",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Population pharmacokinetics and pharmacodynamics of 500 mg oral dose levofloxacin in respiratory tract infection patients

AU - Tanigawara, Yusuke

AU - Shimizu, Takako

AU - Totsuka, Kyoichi

PY - 2009/7

Y1 - 2009/7

N2 - We analyzed levofloxacin(LVFX) population pharmacokinetics, and pharmacokinetics and pharmacodynamics(PK-PD) in Japanese subjects to evaluate a new 500 mg once-daily oral dosage regimen in Japan. Subjects were each orally administered once-daily LVFX 500 mg and plasma concentrations were measured; 1,362 concentrations of LVFX from 49 healthy or renally impaired subjects and 151 patients with respiratory tract infections were used for analysis. Population pharmacokinetic parameters were estimated using a non-linear mixed effects model(NONMEM), applying a 2-compartment model with first-order absorption as a pharmacokinetic model. Covariates were tested for potential influence on LVFX pharmacokinetics. Significant influence was found from creatinine clearance on oral clearance (CL t/F), body weight, and age on the apparent volume of distribution of the central compartment (V1/F), and food intake on absorption constant (k a). Based on the population pharmacokinetic models and the distribution of minimum inhibitory concentration(MIC) for clinical isolates of Streptococcus pneumoniae, LVFX PK-PD parameters in patients administered 500 mg once-daily, 100 mg three-times daily, 200 mg twice or three-times daily were calculated by Monte-Carlo simulation. It showed that 93.5% of patients with 500 mg LVFX once daily reached C max/MIC≥5, whereas 31.4% of those with 100 mg three times daily reached the target. The proportion of patients showing AUC 0-24h/ MIC≥30 exceeded 95% under both dosing regimens. These results indicate that 500 mg LVFX once daily is to be effective comparable to 100 mg three times daily, and is to be more appropriate dose for respiratory tract infection patients to prevent the emergence of LVFX resistance.

AB - We analyzed levofloxacin(LVFX) population pharmacokinetics, and pharmacokinetics and pharmacodynamics(PK-PD) in Japanese subjects to evaluate a new 500 mg once-daily oral dosage regimen in Japan. Subjects were each orally administered once-daily LVFX 500 mg and plasma concentrations were measured; 1,362 concentrations of LVFX from 49 healthy or renally impaired subjects and 151 patients with respiratory tract infections were used for analysis. Population pharmacokinetic parameters were estimated using a non-linear mixed effects model(NONMEM), applying a 2-compartment model with first-order absorption as a pharmacokinetic model. Covariates were tested for potential influence on LVFX pharmacokinetics. Significant influence was found from creatinine clearance on oral clearance (CL t/F), body weight, and age on the apparent volume of distribution of the central compartment (V1/F), and food intake on absorption constant (k a). Based on the population pharmacokinetic models and the distribution of minimum inhibitory concentration(MIC) for clinical isolates of Streptococcus pneumoniae, LVFX PK-PD parameters in patients administered 500 mg once-daily, 100 mg three-times daily, 200 mg twice or three-times daily were calculated by Monte-Carlo simulation. It showed that 93.5% of patients with 500 mg LVFX once daily reached C max/MIC≥5, whereas 31.4% of those with 100 mg three times daily reached the target. The proportion of patients showing AUC 0-24h/ MIC≥30 exceeded 95% under both dosing regimens. These results indicate that 500 mg LVFX once daily is to be effective comparable to 100 mg three times daily, and is to be more appropriate dose for respiratory tract infection patients to prevent the emergence of LVFX resistance.

KW - Levofloxacin

KW - PK-PD

KW - Population pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=69549130909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549130909&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 47

EP - 54

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 2

ER -